MIF蛋白、EMT标记蛋白在肝癌组织中的表达及与临床病理特征、预后的相关性

Expressions of MIF Protein and EMT Marker Proteins in Liver Cancer Tissues and Their Correlation with Clinicopathological Characteristics and Prognosis

目的:探究巨噬细胞移动抑制因子(MIF)、上皮间质转化(EMT)标记蛋白钙黏附蛋白E(E-cadherin)和波形纤维蛋白(Vimentin)在肝癌组织中的表达及与临床病理特征和预后的相关性。方法:选取2016年1月-2018年1月于本院就诊的45例肝癌患者,收集患者肝癌组织和癌旁组织,采用免疫组织化学法检测组织标本中MIF、E-cadherin和Vimentin的表达,对比肿瘤组织和癌旁组织中各分子表达差异,并分析其与临床病理特征和预后的关系。结果:肝癌组织中MIF的阳性率为71.11%高于癌旁正常组织的33.33%,E-cadherin阳性率为24.44%低于癌旁正常组织的62.22%,Vimentin阳性率为64.44%高于癌旁正常组织的31.11%,差异均有统计学意义(P<0.05)。肿瘤分期Ⅲ~Ⅳ期、肿瘤直径≥5 cm、有淋巴结转移和远处转移的肝癌组织中MIF和Vimentin阳性率均较高,E-cadherin阳性率均较低,差异均有统计学意义(P<0.05)。不同性别、年龄、AFP水平和Edmondson分级肝癌患者的MIF、E-cadherin和Vimentin蛋白水平比较,差异均无统计学意义(P>0.05)。MIF阳性患者中位生存期为20.01个月,95%CI为(17.11,23.82)个月,MIF阴性患者中位生存期为25.50个月,95%CI为(17.87,25.50)个月,MIF表达为阴性的肝癌患者预后更好(P=0.028)。E-cadherin阳性患者中位生存期为22.73个月,95%CI为(19.62,22.73)个月,E-cadherin阴性患者中位生存期为16.66个月,95%CI为(13.89,25.50)个月,E-cadherin表达为阳性的肝癌患者预后更好(P=0.040)。Vimentin阳性患者中位生存期为17.11个月,95%CI为(15.55,17.87)个月,Vimentin阴性患者中位生存期为23.88个月,95%CI为(19.62,23.88)个月,Vimentin表达为阴性的肝癌患者预后更好(P=0.032)。结论:MIF蛋白、EMT标记蛋白与肝癌的病情进展有关,可作为预测肝癌预后的重要生物标志物。

Objective:To explore the expressions of macrophage migration inhibitory factor (MIF) and epithelial-mesenchymal transition (EMT) marker proteins E-cadherin and Vimentin in liver cancer tissues and their correlation with clinicopathological characteristics and prognosis.Method:A total of 45 patients with liver cancer admitted to our hospital from January 2016 to January 2018 were selected,and the liver cancer tissues and paracancer tissues of the patients were collected.Immunohistochemistry was used to detect the expressions of MIF,E-cadherin and Vimentin in tissue specimens,and the differences of molecular expressions in tumor tissues and paracancer tissues were compared,and their relationship with clinicopathological features and prognosis were analyzed.Result:The positive rate of MIF in liver cancer tissues was 71.11%,which was higher than 33.33% in adjacent normal tissues,the positive rate of E-cadherin in liver cancer tissues was 24.44%,which was lower than 62.22% in normal adjacent tissues,the positive rate of Vimentin in liver cancer tissues was 64.44%,which was higher than 31.11% in normal adjacent tissues (P<0.05).The positive rates of MIF and Vimentin were higher and the positive rate of E-cadherin were lower in liver cancer tissues with stage Ⅲ-Ⅳ,tumor diameter ≥5 cm,lymph node metastasis and distant metastasis,the differences were statistically significant (P<0.05).There were no significant differences in MIF,E-cadherin and Vimentin protein levels in patients with liver cancer with different genders,ages,AFP levels and Edmondson grade (P>0.05).The median survival time of MIF positive patients was 20.01 months,95%CI (17.11,23.82) months,while MIF negative patients had a median survival of 25.50 months,95%CI (17.87,25.50) months.Patients with negative MIF expression had better prognosis (P=0.028).The median survival time of E-cadherin positive patients was 22.73 months,95%CI (19.62,22.73) months,while E-Cadherin negative patients was 16.66 months,95%CI (13.89,25.50) months.Patients with positive E-cadherin expression had better prognosis (P=0.040).The median survival time of Vimentin positive patients was 17.11 months,95%CI (15.55,17.87) months,while Vimentin negative patients was 23.88 months 95%CI (19.62,23.88) months.Patients with negative Vimentin expression had better prognosis (P=0.032).Conclusion:MIF protein and EMT marker proteins are related to the progression of liver cancer and can be used as important biomarkers to predict the prognosis of liver cancer.